We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





CRP Tracking Predicts Potential Outcome for Hospitalized COVID-19 Patients

By LabMedica International staff writers
Posted on 16 Nov 2020
By tracking the increase in circulating levels of the inflammatory biomarker C-reactive protein, doctors are able to predict whether newly hospitalized COVID-19 patients will suffer respiratory deterioration with the possible need for intubation.

C-reactive protein (CRP) is a ring-shaped, pentameric protein found in blood plasma, whose circulating concentrations rise in response to inflammation. More...
It is an acute-phase protein manufactured in the liver that increases following interleukin-6 (IL-6) secretion by macrophages and T-cells. Its physiological role is to bind to lysophosphatidylcholine expressed on the surface of dead or dying cells (and some types of bacteria) in order to activate the complement system via C1q.

Investigators at Brigham and Women's Hospital (Boston, MA, USA) examined the theory that inflammatory biomarker levels could predict respiratory decline in patients who initially presented with stable disease. For this study, the investigators followed CRP levels in 100 COVID-19 patients admitted to the hospital.

Results revealed that a rapid rise in CRP levels during the first 48-to-72 hours of hospitalization was predictive of subsequent respiratory deterioration and intubation, while steadier CRP levels were observed in patients whose condition remained stable. Increasing CRP during the first 48 hours of hospitalization was a better predictor (with higher sensitivity) of respiratory decline than initial CRP levels.

"We realized that whereas a single CRP lab value from hospital admission was not very practical as a predictor of who might get sicker, tracking the rate of change from Day One to Day Two or Three was a very powerful and very clinically predictive test," said senior author Dr. Edy Yong Kim, instructor in medicine at Brigham and Women's Hospital. "Even though all of these patients looked clinically similar upon admission, as early as 24 hours after hospitalization, the immune systems of patients who would go on to the ICU multiple days later were already inflamed, as measured by these biomarkers. Because of our findings, we changed our guidelines at the Brigham to mandate CRP tracking every day for the first three days of hospitalization so that we could try to identify vulnerable patients and keep a close eye on their inflammation."

The CRP study was published in the October 28, 2020, online edition of the journal Cell Reports Medicine.

Related Links:
Brigham and Women's Hospital


Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
New
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: The GenoPredict assay from Predicta Biosciences is available to Tempus Life Sciences partners to support exploratory research and clinical development programs (photo courtesy of Shutterstock)

Partnership Expands Ultrasensitive WGS Assay for for Hematologic Malignancies and MRD Monitoring

Tempus AI and Predicta Biosciences announced the commercial expansion of a co-branded whole‑genome sequencing assay GenoPredicta, which is intended for comprehensive genomic characterization of hematologic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.